ArcelorMittal SA vs uniQure N.V. Ordinary Shares — how do they compare? ArcelorMittal SA trades at $62.02 (market cap $47.37B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: ArcelorMittal SA is far larger — about 32× uniQure N.V. Ordinary Shares's market cap, and ArcelorMittal SA pays a 0.95% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| MT | QURE | |
|---|---|---|
Market Cap | $47.37B | $1.48B |
Volume | 616,736 | 2,488,780 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $70.59 |
52-Week Low | $36.91 | $9.03 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $56.95B | $728.62M |
Dividend Yield | 0.95% | — |
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $62.49, down 0.73% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with declining revenue from $79.8B in 2022 to $61.4B in 2025, though net income improved to $3.2B. Recent Ukraine plant impairments and missile strikes create operational headwinds, while analyst consensus remains positive with a $74.33 price target representing 19% upside potential.
MT presents a value opportunity with attractive valuation multiples (P/S 0.77, P/B 0.87) and strong cash flow generation, but faces significant geopolitical risks and declining revenue trends. The company's strategic shift toward regional operations and shareholder returns supports long-term potential, though near-term volatility from European demand fluctuations and Ukraine impairments requires careful risk management.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →